Kaisai Biotech (688065): Promoting R&D investment and capacity building to accumulate growth momentum
Cathay Biotech (688065): Q1 main business performance inflection point, actively developing bio-based polyamide and piperidine businesses
Cathay Biotech (688065): Demand recovery in 24Q1 is optimistic about capacity release+strategic cooperation to drive growth
Kaiser Biotech (688065): Demand is under pressure in 2023 24Q1 demand will improve significantly, and there is plenty of space for bio-based polyamides
Kaisai Biotech (688065) 2023 Annual Report and 2024 Quarterly Report Review: Q1 long-chain dibasic acid sales increased, profit increased significantly year-on-year
Kaisai Biotech (688065): 24Q1 performance, year-on-month recovery in demand for long-chain binary acid recovery
Kaiser Biotech (688065): Significant increase in first-quarter results, imminent release of bio-based polyamides
Cathay Biotech (688065): Demand for long-chain binary acids is picking up, Q1 performance is high year-on-month, and bio-based composites accelerate commercial application implementation
Kaisai Biotech (688065): Q1 performance increased significantly over the same period last month and continued to advance
Kaisai Biotech (688065) 24Q1 performance pre-increase review: 24Q1 gradually progresses towards positive fixed growth projects
Cathay Biotech (688065): Demand for long-chain binary acids is picking up, looking forward to commercial application of bio-based composites
Kaisai Biotech (688065) Review: Performance is under pressure due to declining demand for long-chain binary acids, waiting for commercial application of bio-based composites to be implemented
Kaisai Biotech (688065): Constant increase and continuous promotion of bio-based nylon have broad prospects
Kaisai Biotech (688065): Long-chain binary acid production continues to expand, China Merchants bureau's equity investment helps promote the application of bio-based polyamides
Kaisai Biotech (688065): Long-chain binary acid gross profit is declining, performance is under pressure, and the application prospects for bio-based composites are broad
Kaisai Biotech (688065): Q3 performance is under pressure to promote bio-based nylon, and shares can be expected to be repurchased, showing confidence
Kaisai Biotech (688065) Three Quarterly Report Review: Polyamide Applications Accelerate Advancement, Optimistic About the Company's Long-Term Growth
Kaisai Biotech (688065): Demand for long-chain binary acids is weak, short-term performance is under pressure, and the industrialization of bio-based polyamides is expected to accelerate
Kaisai Biotech (688065): Q3 performance is in line with expectations, new materials are waiting to be released
Kaisai Biotech (688065): Second quarter results have improved markedly month-on-month, and the prospects for China Merchants to invest in shares are broad
No Data